About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

LAF 237

Company: The University of Texas Health Science Center at San Antonio
Mechanism: Mechanism not yet reported
Route: Route not yet reported
Recruiting trials: 2 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

2 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details

Recruiting NCT NCT03925701

Clinical Study Evaluating Vildagliptin Versus Vildagliptin/Metformin on NAFLD With DM

Not yet reported Sherief Abd-Elsalam 120 participants Est. completion 2028-12 1 site

Other conditions: dm
View official trial listing →
Recruiting NCT NCT06142656

Efficacy of Vildagliptin Versus Metformin in Poly Cystic Ovary Syndrome

Not yet reported, Not yet reported October 6 University 60 participants Est. completion 2026-02-01 1 site

Other conditions: Poly Cystic Ovary Syndrome
View official trial listing →
Completed NCT NCT00099853

Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes

Not yet reported Novartis Pharmaceuticals 362 participants Est. completion 2008-01 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00099866

Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes

Not yet reported Novartis Pharmaceuticals 570 participants Est. completion 2005-08 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00099892

Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes

Not yet reported Novartis Pharmaceuticals 544 participants Est. completion 2005-09 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00099905

A Clinical Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes

Not yet reported Novartis Pharmaceuticals 639 participants Est. completion 2005-10 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00099918

Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes

Not yet reported Novartis Pharmaceuticals 717 participants Est. completion 2005-09 2 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT00099931

Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes

Not yet reported Novartis Pharmaceuticals 254 participants Est. completion 2005-06 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00099944

Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes

Not yet reported Novartis Pharmaceuticals 515 participants Est. completion 2005-10 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00099957

A Clinical Study to Assess the Effect of Vildagliptin on Postprandial Lipid Parameters in Patients With Type 2 Diabetes

Not yet reported Novartis Pharmaceuticals 38 participants Est. completion 2005-06 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00101673

Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With HbA1c 9-11%

Not yet reported Novartis Pharmaceuticals 251 participants Est. completion 2005-06 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00101712

Efficacy and Safety of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes and Mild Hyperglycemia

Not yet reported Novartis Pharmaceuticals 274 participants Est. completion 2006-05 2 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT00101803

Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Drug Naive Patients With Type 2 Diabetes

Not yet reported Novartis Pharmaceuticals 527 participants Est. completion 2006-01 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00102388

Efficacy and Safety of Vildagliptin Compared to Gliclazide in Drug Naive Patients With Type 2 Diabetes

Not yet reported Novartis Pharmaceuticals 1092 participants 2 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT00102466

Vildagliptin Compared to Gliclazide in Combination With Metformin in Patients With Type 2 Diabetes

Not yet reported Novartis Pharmaceuticals 1007 participants Est. completion 2009-01 2 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT00106340

Vildagliptin Compared to Glimepiride in Combination With Metformin in Patients With Type 2 Diabetes

Not yet reported Novartis Pharmaceuticals 3118 participants Est. completion 2008-05-20 2 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT00110240

Efficacy and Safety of Vildagliptin Compared to Acarbose in Drug Naive Patients With Type 2 Diabetes

Not yet reported Novartis Pharmaceuticals 594 participants Est. completion 2006-10 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00120536

Efficacy and Safety of Three Doses of Vildagliptin in Drug Naive Patients With Type 2 Diabetes

Not yet reported Novartis 288 participants Est. completion 2006-07 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00138515

Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Metformin in Patients With Type 2 Diabetes

Not yet reported Novartis 418 participants Est. completion 2006-05 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00138541

Extension to a Study to Assess the Efficacy and Safety of Three Doses of Vildagliptin in Patients With Type 2 Diabetes

Not yet reported Novartis 440 participants Est. completion 2006-04 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00138554

Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes

Not yet reported Novartis 318 participants Est. completion 2006-07 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00138567

Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Metformin in Drug Naive Patients With Type 2 Diabetes

Not yet reported Novartis 530 participants Est. completion 2006-08 2 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT00138580

Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Glimepiride in Patients With Type 2 Diabetes

Not yet reported Novartis 345 participants Est. completion 2006-04 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00138593

Extension to a Study of the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes With Hemoglobin A1c (HbA1c) 9-11%

Not yet reported Novartis 180 participants Est. completion 2006-07 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00138606

Extension to a Study on the Efficacy and Safety of Vildagliptin in Combination With Insulin in Patients With Type 2 Diabetes

Not yet reported Novartis 179 participants Est. completion 2006-01 2 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT00138619

Extension to a Study on the Efficacy and Safety of Vildagliptin Compared to Rosiglitazone in Drug Naive Patients With Type 2 Diabetes

Not yet reported Novartis 478 participants Est. completion 2007-04 2 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT00230464

Acute Metabolic Effects of LAF 237 in Type 2 Diabetics

Not yet reported The University of Texas Health Science Center at San Antonio 16 participants Est. completion 2005-09 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00237237

Vildagliptin Compared to Pioglitazone in Combination With Metformin in Patients With Type 2 Diabetes

Not yet reported Novartis 588 participants 2 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT00237250

Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance

Not yet reported Novartis 171 participants Est. completion 2006-07 1 site

Other conditions: Prediabetic State
View official trial listing →
Completed NCT NCT00238498

A Clinical Study to Assess the Efficacy and Safety of Vildagliptin in Patients With Type 2 Diabetes

Not yet reported Novartis 291 participants Est. completion 2005-06

Type 2 diabetes
View official trial listing →
Completed NCT NCT00260156

A Clinical Study to Assess the Effect of Vildagliptin on Beta Cell Function in Drug Naive Patients With Type 2 Diabetes

Not yet reported Novartis Pharmaceuticals 59 participants Est. completion 2008-12 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00300287

A 56-Week Extension to a Clinical Study to Assess the Efficacy and Safety of Vildagliptin Compared to Placebo in Drug Naive Patients With Type 2 Diabetes and Mild Hyperglycemia

Not yet reported Novartis 150 participants Est. completion 2007-06-26 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00312130

A Study to Evaluate the Effects of Vildagliptin on the Insulin Response to Glucose in Subjects With Pre-diabetes

Not yet reported Novartis 20 participants Est. completion 2006-11 1 site

Prediabetes
View official trial listing →
Completed NCT NCT00325117

To Assess the Efficacy and Safety of Vildagliptin as Add-on Therapy to Sulfonylurea in Patients With Type 2 Diabetes Inadequately Controlled With Sulfonylurea Monotherapy

Not yet reported Novartis 200 participants 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00325429

Long-Term Safety Study of Vildagliptin in Patients With Type 2 Diabetes

Not yet reported Novartis 150 participants 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00351507

A Study to Assess the Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes

Not yet reported Novartis Pharmaceuticals 10 participants Est. completion 2006-02 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00351546

A Study to Assess the Effects of DPP-4 Inhibition on Insulin Sensitivity in Type 2 Diabetes

Not yet reported Novartis 12 participants Est. completion 2005-12

Type 2 diabetes
View official trial listing →
Completed NCT NCT00351585

A Study to Evaluate the Effect of Vildagliptin on the Maximum Insulin Secretion in Patients With Type 2 Diabetes

Not yet reported Novartis 39 participants Est. completion 2005-09

Type 2 diabetes
View official trial listing →
Completed NCT NCT00351832

A Study To Compare the Effect of Vildagliptin Compared to Placebo in Patients With Type 2 Diabetes

Not yet reported Novartis 236 participants 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00351884

Efficacy of Vildagliptin 100 MG as Compared to Placebo as Add-on to Metformin in Patients With Type 2 Diabetes

Not yet reported Novartis Pharmaceuticals 370 participants 2 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT00368134

To Compare the Efficacy and Safey of Vildagliptin Compared to Voglibose in Patients With Type 2 Diabetes

Not yet reported Novartis 370 participants 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00380380

A Study to Assess the Acute Effects of Vildagliptin on Gastric Emptying in Patients With Type 2 Diabetes.

Not yet reported Novartis 18 participants Est. completion 2006-11 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00380445

Effect of Vildagliptin on Fat and Muscle Metabolism in Patients With Type 2 Diabetes

Not yet reported Novartis 21 participants Est. completion 2007-04 2 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT00382096

Efficacy of Fixed Combination Therapy of Vildagliptin and Metformin Compared to the Individual Monotherapy Components in Drug Naive Patients With Type 2 Diabetes

Not yet reported Novartis Pharmaceuticals 1179 participants Est. completion 2008-06-03 2 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT00383578

Efficacy and Safety of Vildagliptin Compared to Metformin in Elderly Drug Naive Patients With Type 2 Diabetes

Not yet reported Novartis Pharmaceuticals 335 participants 2 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT00389415

Long Term Safety of Vildagliptin (100mg qd) In Patients With Type 2 Diabetes

Not yet reported Novartis 150 participants 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00390520

Efficacy and Safety of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes

Not yet reported Novartis 28 participants Est. completion 2007-09 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00396071

Efficacy and Safety of Vildagliptin Compared to Placebo on the Incretin Effect in Patients With Type 2 Diabetes Treated With Metformin

Not yet reported Novartis Pharmaceuticals 22 participants 2 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT00396227

Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone

Not yet reported Novartis Pharmaceuticals 2665 participants 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00396357

Efficacy/Safety of Vildagliptin and Metformin Combination Therapy in Patients With Type 2 Diabetes Not Well Controlled With Metformin Alone

Not yet reported Novartis Pharmaceuticals 914 participants 2 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT00414947

Bioequivalence of Vildagliptin Tablet Manufactured in China Compared to Imported Vildagliptin Tablet in Chinese Healthy Volunteers

Not yet reported Novartis 30 participants 1 site

Other conditions: Healthy
View official trial listing →
Completed NCT NCT00419887

Safety, Tolerability, Effect of Vildagliptin and How the Body Changes the Blood Level of Vildagliptin in Healthy Chinese Volunteers

Not yet reported Novartis 60 participants 1 site

Other conditions: Healthy
View official trial listing →
Completed NCT NCT00468039

A Sub-study to LMF237A2302 to Assess the Effect of 24 Weeks Treatment With Initial Combination of Vildagliptin Plus Metformin

Not yet reported Novartis 94 participants Est. completion 2008-06-06 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00494884

Vildagliptin 100 mg Once Daily vs. Placebo as add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

Not yet reported Novartis Est. completion 2008-07 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00567047

Pharmacokinetic Study of Vildagliptin in Patients With Renal Impairment

Not yet reported Novartis 96 participants 6 sites

Other conditions: Type-2 Diabetes
View official trial listing →
Completed NCT NCT00572650

Pharmacokinetic Study of LAF237 and Its Metabolites in Mild Renal Impaired Patients

Not yet reported Novartis 29 participants Est. completion 2007-11 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00616811

Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency

Not yet reported Novartis 148 participants Est. completion 2010-10 79 sites

Type 2 diabetes
View official trial listing →
Terminated NCT NCT00633997

Assessment of the Skin-concentration of Vildagliptin 50 mg Every 12 Hours for 10 Days in Healthy Subjects and Patients With Type 2 Diabetes

Not yet reported, Not yet reported Novartis 22 participants 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00646542

Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency

Not yet reported Novartis 525 participants 12 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT00651105

Effect of LAF237 on Glucagon Secretion in Patients With Type 2 Diabetes and in Healthy Subjects

Not yet reported Novartis 63 participants 2 sites

Other conditions: Type-2 Diabetes, Healthy
View official trial listing →
Completed NCT NCT00728351

Efficacy and Safety of Fixed Combination Therapy of Vildagliptin and Metformin (25/1000 mg Bid) in Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy (HbA1c 7.0-9.5%)

Not yet reported Novartis Pharmaceuticals 317 participants 63 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT00765830

Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency (28 Week Extension)

Not yet reported Novartis 349 participants Est. completion 2011-04 90 sites

Type 2 diabetes Other conditions: Renal Insufficiency
View official trial listing →
Completed NCT NCT00770081

Safety and Tolerability of Vildagliptin Versus Sitagliptin in Patients With Type 2 Diabetes and Severe Renal Insufficiency (28-week Extension Study)

Not yet reported Novartis 75 participants Est. completion 2011-04 87 sites

Type 2 diabetes Other conditions: Renal Insufficiency
View official trial listing →
Completed NCT NCT00818571

Pharmacokinetics of Vildagliptin in Mild, Moderate and Severe Renal Impaired Patients

Not yet reported, Not yet reported Novartis Pharmaceuticals 96 participants 1 site

Other conditions: Renal Impairment, Diabetes
View official trial listing →
Completed NCT NCT00821977

Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes

Not yet reported, Not yet reported Novartis 338 participants Est. completion 2010-10 176 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT00822211

Efficacy of add-on Therapy With Vildagliptin in Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy

Not yet reported Novartis 404 participants Est. completion 2009-12 17 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT00860288

Efficacy and Long-Term Safety of Vildagliptin as Add-on Therapy to Metformin in Patients With Type 2 Diabetes

Not yet reported, Not yet reported Novartis Pharmaceuticals 1988 participants Est. completion 2011-03 187 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT00894868

Effect of Vildagliptin on Left Ventricular Function in Patients With Type 2 Diabetes and Congestive Heart Failure

Not yet reported Novartis Pharmaceuticals 798 participants Est. completion 2012-08 93 sites

Heart failure Other conditions: Type II Diabetes Mellitus
View official trial listing →
Withdrawn NCT NCT00936234

Functional Improvement of Progenitor Cells and Endothelial Function by Vildagliptin in Diabetes Mellitus (FINNjA-DM).

Not yet reported, Not yet reported Johann Wolfgang Goethe University Hospital Est. completion 2013-05 1 site

Other conditions: SDF-1 is an Important Cytokine for Neovascularization. Cleavage of SDF-1 is Reduced by DPPIV Inhibitors
View official trial listing →
Completed NCT NCT00952991

The Effects of LAF237 on Gastric Function in Type 2 Diabetes

Not yet reported Mayo Clinic 18 participants Est. completion 2006-02 1 site

Other conditions: Diabetes Mellitus, Non-Insulin-Dependent
View official trial listing →
Completed NCT NCT00975065

Galvus on Met Phase 4 Study : Study to Evaluate the Efficacy and Safety of Early Combination of Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus

Not yet reported Handok Inc. 266 participants Est. completion 2012-04 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT00980356

Vildagliptin in New Onset Diabetes After Transplantation

Not yet reported Medical University of Vienna 32 participants Est. completion 2012-12 1 site

Other conditions: Diabetes Mellitus
View official trial listing →
Completed NCT NCT01000688

Vildagliptin and Endothelium-dependent Vasodilatation

Not yet reported Radboud University Medical Center 16 participants Est. completion 2010-10 1 site

Type 2 diabetes Other conditions: Endothelial Dysfunction
View official trial listing →
Status unknown NCT NCT01018602

PINGUIN (Postpartum Intervention in Women With Gestational Diabetes Using Insulin)

Not yet reported Institut fur Diabetesforschung, Munich, Germany 140 participants Est. completion 2015-06 1 site

Other conditions: Insulin-dependent Gestational Diabetes
View official trial listing →
Completed NCT NCT01065298

Efficacy Of Autologous Bone Marrow Derived Stem Cell Transplantation In Patients With Type 2 Diabetes Mellitus-2

Post Graduate Institute of Medical Education and Research, Chandigarh 30 participants Est. completion 2011-07 1 site

Type 2 diabetes
View official trial listing →
Status unknown NCT NCT01083992

Role of Vitagliptin and Vitamin D in the Treatment of Non Alcoholic Fatty Liver Disease (NAFLD)

Not yet reported Ziv Hospital 60 participants Est. completion 2013-06 1 site

Other conditions: Non-Alcoholic Fatty Liver Disease
View official trial listing →
Completed NCT NCT01099137

Effect of Vildagliptin in Type 2 Diabetes Treated With Sulphonylurea and Metformin

Not yet reported Seoul National University Bundang Hospital 344 participants Est. completion 2013-05 1 site

Other conditions: Diabetes
View official trial listing →
Completed NCT NCT01122641

The Vascular Effects of Vildagliptin in Insulin Resistant Individuals

Not yet reported Royal Devon and Exeter NHS Foundation Trust 15 participants Est. completion 2014-08-01 1 site

Other conditions: Insulin Resistance, Microvascular Disease
View official trial listing →
Completed NCT NCT01147276

Vildagliptin and the Glucagon Response to Hypoglycemia in Type 1 Diabetes

Not yet reported Lund University 28 participants Est. completion 2011-12 1 site

Other conditions: Diabetes, Hypoglycemia
View official trial listing →
Completed NCT NCT01159249

Long-term Safety Study of Vildagliptin in Patients With Type 2 Diabetes

Not yet reported Novartis Pharmaceuticals 245 participants Est. completion 2012-01 24 sites

Type 2 diabetes
View official trial listing →
Status unknown NCT NCT01176708

Intact Liver Innervation and Glucose and Glucagon-like Peptide-1 (GLP-1) Induced Insulin Secretion

Not yet reported University Hospital, Gentofte, Copenhagen 30 participants Est. completion 2012-12 1 site

Other conditions: Liver Transplantation
View official trial listing →
Status unknown NCT NCT01176760

Intact Vagal Innervation for and Glucagon-like Peptide-1 (GLP-1) Effects

Not yet reported University Hospital, Gentofte, Copenhagen 30 participants Est. completion 2012-12 1 site

Other conditions: Vagotomy, Truncal
View official trial listing →
Completed NCT NCT01193296

Glycemic Holter Study (Continuous Glucose Monitoring) -

Not yet reported Novartis 36 participants Est. completion 2011-06 7 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT01196546

Efficacy and Safety of Combination Therapy of Vildagliptin/Metformin in Patients in Type 2 Diabetes Mellitus (T2DM)

Not yet reported Novartis 161 participants Est. completion 2011-10 8 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT01219400

Vildagliptin and the Glucagon Response to Hypoglycemia in Insulin-Treated Patients With Type 2 Diabetes

Not yet reported Lund University 28 participants Est. completion 2013-12 1 site

Other conditions: Diabetes
View official trial listing →
Completed NCT NCT01224366

Efficacy and Safety of Vildagliptin as add-on Therapy to Insulin in Patients With Type 2 Diabetes Mellitus

Not yet reported Novartis 448 participants Est. completion 2011-10 66 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT01233622

Safety and Efficacy of Galvus as add-on Therapy to Metformin Plus Glimepiride

Not yet reported Novartis 317 participants Est. completion 2011-11 55 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT01238978

Phase 4 Study in the Elderly Patients With T2DM

Not yet reported Novartis 46 participants Est. completion 2011-12 15 sites

Type 2 diabetes Other conditions: Elderly
View official trial listing →
Completed NCT NCT01242228

A Study to Assess the Safety and Efficacy of ASP1941 in Combination With Dipeptidyl Peptidase-4 (DPP-4) Inhibitor in Type 2 Diabetic Patients

Not yet reported Astellas Pharma Inc 106 participants Est. completion 2012-06-06 6 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT01257451

Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients

Not yet reported Novartis Pharmaceuticals 431 participants Est. completion 2012-03 46 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT01262586

Vildagliptin Glycemic Profiles Assessment Using a Continuous Glucose Monitoring Device.

Not yet reported Novartis Pharmaceuticals 24 participants Est. completion 2011-03 1 site

Other conditions: Type II Diabetes Mellitus
View official trial listing →
Completed NCT NCT01309698

Drug Interaction of Vildagliptin (LAF237) With Voglibose in Japanese Patients With Type 2 Diabetes

Not yet reported Novartis Pharmaceuticals 24 participants 1 site

Type 2 diabetes
View official trial listing →
Status unknown NCT NCT01339143

Compare the Effect of DPP-IV Inhibitor or TZD on Glycemic Variability and Oxidative Stress in Patient With 2 Diabetes

Not yet reported Korea University Anam Hospital 80 participants Est. completion 2013-05 1 site

Other conditions: Diabetes Mellitus, Oxidative Stress
View official trial listing →
Completed NCT NCT01346254

Glucose Control in Pre-Diabetic Renal Transplant Patients

Not yet reported Marcus Saemann 51 participants Est. completion 2011-11 1 site

Prediabetes Other conditions: Kidney Transplantation
View official trial listing →
Completed NCT NCT01356381

Study to Assess the Effect of 24 Weeks of Treatment With Vildagliptin in Patients With Type 2 Diabetes

Not yet reported Novartis Pharmaceuticals 43 participants Est. completion 2013-08 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT01357252

Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes

Not yet reported Novartis Pharmaceuticals 279 participants Est. completion 2013-01 18 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT01398592

Vildagliptin Versus Sitagliptin - Differences in Fasting Plasma Glucose Lowering Efficacy

Not yet reported Novartis Pharmaceuticals 187 participants Est. completion 2012-06 15 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT01404676

The Effect of Vildagliptin Based Treatment Versus Sulfonylurea on Glycemic Variability, Oxidative Stress, GLP-1, and Endothelial Function in Patients With Type 2 Diabetes

Not yet reported Samsung Medical Center 34 participants Est. completion 2012-05 1 site

Type 2 diabetes
View official trial listing →
Status unknown NCT NCT01426737

The Swiss Glucose Variability Study

Not yet reported University of Zurich 50 participants Est. completion 2013-01 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT01426802

Vildagliptin 50 mg Twice Daily in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin

Not yet reported Novartis Pharmaceuticals 150 participants Est. completion 2011-04 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT01452113

Effect of Autonomic Neuropathy on the Efficacy of a DPP-IV Inhibitor (Galvus) Therapy

Not yet reported University Hospital, Toulouse 21 participants Est. completion 2013-03 1 site

Other conditions: Diabetes Mellitus
View official trial listing →
Completed NCT NCT01472432

DPP IV Inhibition Facilitates Healing of Chronic Foot Ulcers in Type 2 Diabetes

Not yet reported University of Campania Luigi Vanvitelli 106 participants Est. completion 2016-01 1 site

Other conditions: Chronic Foot Ulcers
View official trial listing →
Completed NCT NCT01497522

Efficacy and Safety of Vildagliptin as add-on Therapy to Metformin in Patients With Type 2 Diabetes

Not yet reported Novartis Pharmaceuticals 183 participants Est. completion 2013-02 20 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT01518101

Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both Medications

Not yet reported Novartis Pharmaceuticals 62 participants Est. completion 2012-10 8 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT01528254

VERIFY:A Study to Compare Combination Regimen With Vildagliptin & Metformin Versus Metformin in Treatment-naïve Patients With Type 2 Diabetes Mellitus

Not yet reported Novartis Pharmaceuticals 2004 participants Est. completion 2019-04-04 227 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT01537120

Evaluation of Continuous Glucose Monitoring in Participants With Type 2 Diabetes Mellitus (MK-0000-258 AM2)

Not yet reported Merck Sharp & Dohme LLC 25 participants Est. completion 2012-10

Type 2 diabetes
View official trial listing →
Completed NCT NCT01541956

Efficacy of VIldagliptin aS an Add-on Therapy to Metformin Compared to Metformin Up-TitratION in Chinese Patients With Type 2 Diabetes.(VISION)

Not yet reported Novartis Pharmaceuticals 3091 participants Est. completion 2013-12 1 site

Type 2 diabetes
View official trial listing →
Status unknown NCT NCT01559025

Evaluation of Vildagliptin (Galvus®) as add-on to Insulin in New-onset Type 1 Diabetes Mellitus

Not yet reported Federal University of São Paulo 44 participants Est. completion 2017-03 1 site

Other conditions: Type 1 Diabetes, Insulin Dependent Diabetes, Juvenile Onset Diabetes Mellitus, Autoimmune Diabetes
View official trial listing →
Status unknown NCT NCT01565096

Effect of Adding Vildagliptin on Beta Cell Function and Cardiovascular Risk Markers in Patients With Moderate Metabolic Control During Metformin Monotherapy

Not yet reported ikfe-CRO GmbH 44 participants 1 site

Other conditions: Diabetes Mellitus Type II
View official trial listing →
Completed NCT NCT01582230

Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes Mellitus

Not yet reported Novartis Pharmaceuticals 293 participants Est. completion 2013-05 21 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT01582243

Safety and Efficacy of Vildagliptin Plus Metformin (SPC) Treatment in Type 2 Diabetes Mellitus Patients

Not yet reported Novartis Pharmaceuticals 40 participants Est. completion 2015-09 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT01582308

A Study Comparing the Pharmacokinetic and Pharmacodynamic Profiles for Sitagliptin, Saxagliptin and Vildagliptin in Participants With Type 2 Diabetes Mellitus (T2DM) (MK-0431-142)

Not yet reported Merck Sharp & Dohme LLC 22 participants Est. completion 2012-12-14

Type 2 diabetes
View official trial listing →
Status unknown NCT NCT01588587

DPP-IV Inhibitors Underlying Mechanism of Cancer in Diabetic Patients

Nagaoka Red Cross Hospital 500 participants Est. completion 2017-12 2 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT01604213

Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics With Coronary Artery Disease

Not yet reported Sheba Medical Center 60 participants Est. completion 2016-04 1 site

Type 2 diabetes Other conditions: Ischemic Heart Disease
View official trial listing →
Completed NCT NCT01649466

Safety and Efficacy of Vildagliptin Versus NPH Insulin add-on to Glimepiride in Type 2 Diabetes Mellitus Patients.

Not yet reported Novartis Pharmaceuticals 162 participants Est. completion 2013-10 53 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT01679899

Effect of Anti-diabetic Drugs on Bone Metabolism and Glycemic Variability

Not yet reported Centro de Diabetes Curitiba Ltda 56 participants Est. completion 2015-10 1 site

Type 2 diabetes Other conditions: Menopause, Osteoporosis, Osteopenia
View official trial listing →
Completed NCT NCT01686932

Vildagliptin vs Sitagliptin add-on to Insulin - Impact on Glycemic Profile and Correlation of Hypoglycemic Episodes and Heart Function

Not yet reported Novartis Pharmaceuticals 51 participants Est. completion 2014-09 11 sites

Type 2 diabetes
View official trial listing →
Status unknown NCT NCT01703637

Efficacy and Safety Comparative Study of Sitagliptin,Vildagliptin and Saxagliptin

Not yet reported Lin Liao 300 participants 8 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT01757587

Galvus (Vildagliptin) vs Placebo in Combination With Metformin and Insulin

Not yet reported Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète 39 participants Est. completion 2015-03 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT01758380

Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan

Not yet reported Novartis Pharmaceuticals 557 participants Est. completion 2013-09 68 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT01759823

Bone Marrow Derived Stem Cell Transplantation in T2DM

Not yet reported, Not yet reported Post Graduate Institute of Medical Education and Research, Chandigarh 30 participants Est. completion 2015-10 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT01766778

Early add-on Vildagliptin in Patients With Type 2 Diabetes Inadequately Controlled by Metformin

Not yet reported Novartis Pharmaceuticals 117 participants Est. completion 2015-10-22 4 sites

Other conditions: Type-2 Diabetes Mellitus
View official trial listing →
Completed NCT NCT01811485

Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy

Not yet reported Novartis Pharmaceuticals 171 participants Est. completion 2014-02 30 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT01812122

Effects of Vildagliptine and Glimepiride on Glucose Variability

Not yet reported Seoul National University Hospital 16 participants Est. completion 2015-10 1 site

Other conditions: Diabetes Mellitus, Non-Insulin-Dependent
View official trial listing →
Completed NCT NCT01822548

Effect of Vildagliptin vs. Glibenclamide on Circulating Endothelial Progenitor Cell Number Type 2 Diabetes

Not yet reported Azienda Ospedaliero-Universitaria di Parma 64 participants Est. completion 2015-01 2 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT01827280

Acute and Short-term Chronic Effects of Galvus (Vildagliptin) in Diabetes Type 2 Obese Women

Not yet reported Rio de Janeiro State University 40 participants Est. completion 2016-11 1 site

Other conditions: 1- Microvascular Function, 2-oxidative Stress, 3-inflammation
View official trial listing →
Terminated NCT NCT01862263

Effect of 13-Week Treatment With Vildagliptin as Add-On Therapy to Improve Glucose Variability in Type II Diabetes

Not yet reported Novartis Pharmaceuticals 191 participants Est. completion 2015-07 13 sites

Type 2 diabetes
View official trial listing →
Status unknown NCT NCT01867502

Effects of Vildagliptin Versus Glibenclamide on Glycemia After Exercise in Patients With Type 2 Diabetes

Not yet reported Hospital de Clinicas de Porto Alegre 20 participants Est. completion 2015-08 1 site

Type 2 diabetes Other conditions: Hypoglycemic Agents, Diabetic Blood Glucose Monitoring, Exercise
View official trial listing →
Completed NCT NCT01871558

Vildagliptin/Metformin in T2DM Patients Starting Basal Insulin

Not yet reported Novartis Pharmaceuticals 42 participants Est. completion 2015-02 19 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT01882907

Safety and Efficacy Study to Compare Vildagliptin to Pioglitazone as Adding on Metformin in Type 2 Diabetes

Not yet reported Pusan National University Hospital 287 participants Est. completion 2013-03 15 sites

Type 2 diabetes
View official trial listing →
Terminated NCT NCT01910441

Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients

Not yet reported Novartis Pharmaceuticals 95 participants Est. completion 2014-09

Type 2 diabetes
View official trial listing →
Status unknown NCT NCT01922492

Effect of Islet Autotransplantation Compared to Oral Antidiabetic Drug.

Not yet reported Seoul National University Hospital 28 participants Est. completion 2017-12 1 site

Other conditions: Partial Pancreatectomy Due to Benign Pancreatic Neoplasm
View official trial listing →
Completed NCT NCT01963130

Does Vildagliptin Affect Portal Vein Pressure In Patients With Type 2 Diabetes Mellitus? A Cross Sectional Study

Bezmialem Vakif University 97 participants Est. completion 2013-07 1 site

Other conditions: Drug Mechanism, Drug Usage
View official trial listing →
Completed NCT NCT02002221

Study of Efficacy and Safety of Vildagliptin as add-on Insulin Therapy in T2DM Patients

Not yet reported Novartis Pharmaceuticals 156 participants Est. completion 2015-02 31 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT02007278

Glycemic Excursions in Type 2 Diabetic Patients With Vildagliptin and Metformin Versus Vildagliptin and Glimepiride

Not yet reported Novartis Pharmaceuticals 40 participants Est. completion 2016-02-22 8 sites

Type 2 diabetes Other conditions: Hypoglycemia
View official trial listing →
Completed NCT NCT02089438

DPP-4 Inhibition, Incretins and Islet Function

Not yet reported Lund University 24 participants Est. completion 2017-08 1 site

Type 2 diabetes
View official trial listing →
Status unknown NCT NCT02142309

Glycemic Durability After Metformin Failure

Not yet reported University of Campania Luigi Vanvitelli 450 participants Est. completion 2017-01 2 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT02145611

Vildagliptin vs. Glibenclamide in Endothelial Function in Type 2 Diabetes and Hypertension

Not yet reported Dr. José Fernando Vilela-Martin MD PhD 50 participants Est. completion 2016-05 1 site

Type 2 diabetes Other conditions: Hypertension, Endothelial Dysfunction
View official trial listing →
Completed NCT NCT02176681

A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM

Not yet reported University Hospital, Strasbourg, France 70 participants Est. completion 2017-10 13 sites

Type 2 diabetes
View official trial listing →
Terminated NCT NCT02244164

Pathophysiological Study of the Increase in Pancreatic Volume in Type 2 Diabetes Treatments.

Not yet reported Erasme University Hospital 5 participants Est. completion 2023-02-13 1 site

Type 2 diabetes Other conditions: Incretinomimetics, Pancreas
View official trial listing →
Completed NCT NCT02312427

DPP-4 Inhibitor and Serum BNP Level of Diabetic Patients With Congestive Heart Failure

Not yet reported Mitsui Memorial Hospital 10 participants Est. completion 2016-03 1 site

Heart failure Other conditions: Diabetes Mellitus
View official trial listing →
Completed NCT NCT02343926

Phase 3 Study to Compare the Efficacy and Safety of Gemigliptin and Vildagliptin as Add-on Therapy to Metformin in People With Type 2 Diabetes Inadequately Controlled With Metformin

Not yet reported Sanofi 443 participants Est. completion 2016-04 1 site

Type 2 diabetes
View official trial listing →
Status unknown NCT NCT02368704

Role of Endoplasmic Reticulum Stress in the Pathophysiology of Type 2 Diabetes

Assistance Publique - Hôpitaux de Paris 40 participants Est. completion 2016-11 1 site

Type 2 diabetes Other conditions: Endoplasmic Reticulum Stress
View official trial listing →
Completed NCT NCT02456428

Incretin-based Drugs and the Risk of Heart Failure

Canadian Network for Observational Drug Effect Studies, CNODES 1499650 participants Est. completion 2015-05 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT02475070

Vildagliptin Versus Dapagliflozin on Glucagon

Not yet reported Lund University 28 participants Est. completion 2017-06 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT02475499

Incretin-based Drugs and Pancreatic Cancer

Canadian Network for Observational Drug Effect Studies, CNODES 886172 participants Est. completion 2015-04 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT02476760

Incretin-based Drugs and Acute Pancreatitis

Canadian Network for Observational Drug Effect Studies, CNODES 1417914 participants Est. completion 2015-04 1 site

Type 2 diabetes
View official trial listing →
Status unknown NCT NCT02528019

Metabolic and Cardiovascular Effects of Dipeptidyl Peptidase-4 (DPP-4) or Sodium-glucose Co-transporter Type 2 (SGLT2) Inhibitors

Not yet reported Kurume University 100 participants Est. completion 2018-08 1 site

Other conditions: Effects of the DPP-4 Inhibitors or SGLT2 Inhibitors on the Protective Actions for Diabetic Complications
View official trial listing →
Completed NCT NCT02639130

GLP-1 Mediating DPP-4 Inhibition in Type 2 Diabetes

Not yet reported Diabeteszentrum Bad Lauterberg im Harz 67 participants Est. completion 2010-01 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT02749032

Feed-Back Suppression of Meal-Induced Glucagon-like Peptide 1 (GLP-1) Secretion

Not yet reported Michael A. Nauck 24 participants 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT02803892

Monotherapy With Rapamycin in Long-standing Type 1 Diabetes

Not yet reported Piemonti Lorenzo 55 participants Est. completion 2019-03 1 site

Other conditions: Diabetes Mellitus, Type 1
View official trial listing →
Completed NCT NCT02816970

Bioequivalence Study of Vildagliptin From Gliptus 50 mg Tablet (EVA Pharma, Egypt) and Galvus 50 mg Tablet (NOVARTIS PHARMA, GERMANY)

Not yet reported Genuine Research Center, Egypt 24 participants Est. completion 2014-03 1 site

Other conditions: Healthy
View official trial listing →
Completed NCT NCT02832999

Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 Diabetes

Not yet reported Yaounde Central Hospital 14 participants Est. completion 2016-12 1 site

Type 2 diabetes
View official trial listing →
Status unknown NCT NCT02849899

Prevention of Diabetes After Transplantation by Vildagliptin in the Early Post-transplant Period

Not yet reported Centre Hospitalier Universitaire de Besancon 186 participants Est. completion 2024-12 1 site

Other conditions: Disorder Related to Renal Transplantation, Diabetes
View official trial listing →
Completed NCT NCT02853630

A Clinical Trial to Study the Effects of Two Drugs, Vildagliptin and Metformin in Patients With Type 2 Diabetes Mellitus

Not yet reported India Diabetes Research Foundation & Dr. A. Ramachandran's Diabetes Hospitals 203 participants Est. completion 2018-12 6 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT02862470

Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients

National Taiwan University Hospital 22 participants Est. completion 2020-08-24

Other conditions: Thyroid Cancer
View official trial listing →
Status unknown NCT NCT02999841

Effect of Acarbose and Vildagliptin on Visceral Fat Distribution in Newly Diagnosed Type 2 Diabetes Patients

Not yet reported Peking University 100 participants Est. completion 2018-01 1 site

Type 2 diabetes Other conditions: Obesity
View official trial listing →
Completed NCT NCT03014479

Study of the QOL Evaluation of Trelagliptin in Patients With Type 2 Diabetes Mellitus

Not yet reported Takeda 219 participants Est. completion 2017-10-21 27 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT03088670

Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.

Not yet reported SatRx LLC 299 participants Est. completion 2014-10-03 27 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT03178591

Effects of DPP4 Inhibitor Versus SGLT2 Inhibitor

Not yet reported Chiang Mai University 43 participants Est. completion 2018-07 1 site

Type 2 diabetes Other conditions: Ischemic Heart Disease
View official trial listing →
Completed NCT NCT03253562

Metformin Versus Vildagliptin for Diabetic Hypertensive Patients

Not yet reported MTI University 120 participants Est. completion 2017-08-01 1 site

Other conditions: Reducing the Elevated Blood Pressure for Diabetic Hypertensive Patients
View official trial listing →
Completed NCT NCT03492580

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

Janssen Research & Development, LLC 714582 participants Est. completion 2018-06-25 1 site

Type 2 diabetesCardiovascular disease
View official trial listing →
Completed NCT NCT03500900

Vildagliptin on Gastric Accommodation

Not yet reported Universitaire Ziekenhuizen KU Leuven 20 participants Est. completion 2017-01-01

Other conditions: Healthy
View official trial listing →
Status unknown NCT NCT03563794

Efficacy and Safety of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion in Uncontrolled Type 2 Diabetes

Not yet reported The First Affiliated Hospital of Xiamen University 400 participants Est. completion 2019-12-10 1 site Stand-alone

Type 2 diabetes
View official trial listing →
Withdrawn NCT NCT03577184

Evaluating the Glycemic Control wIth Vildagliptin and Metformin Combination Therapy.

Clinision Est. completion 2019-03

Type 2 diabetes
View official trial listing →
Completed NCT NCT03693560

Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD

Not yet reported Damanhour University 80 participants Est. completion 2019-10-10 1 site

Cardiovascular diseaseType 2 diabetes
View official trial listing →
Status unknown NCT NCT03804411

Prognostic Predictors of Response to Hypoglycemic Therapy

Not yet reported Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health 800 participants Est. completion 2020-05 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT03819127

Vildagliptin in Older Adults With Diabetes and Mild Cognitive Impairment

Not yet reported University of Catania 60 participants Est. completion 2016-09

Other conditions: Mild Cognitive Impairment
View official trial listing →
Completed NCT NCT03918148

Gliflozins and Cardiovascular Risk Factors in Type 2 Diabetes (GIOIA)

University of Campania Luigi Vanvitelli 1150 participants Est. completion 2023-12-31 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT03939624

Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors and Risk of Cardiovascular Events

Canadian Network for Observational Drug Effect Studies, CNODES 419734 participants Est. completion 2019-10-01 1 site

Type 2 diabetesCardiovascular diseaseHeart failure Other conditions: Cardiovascular Death, All-Cause Mortality
View official trial listing →
Completed NCT NCT03958591

Impact of Short-term Intensive De-escalation Therapy on Long-term Regimen Simplification

Not yet reported Yanbing Li 276 participants Est. completion 2026-03-31 1 site

Other conditions: Diabetes type2
View official trial listing →
Completed NCT NCT03983551

Comparing the Renal Effect of Dipeptidyl-peptidase 4 Inhibitors and Sulfonylureas

Not yet reported Changhua Christian Hospital 101 participants Est. completion 2018-02-28

Type 2 diabetes Other conditions: Proteinuria
View official trial listing →
Completed NCT NCT04017221

Safety of Sodium-glucose Cotransporter 2 (SGLT2) Inhibitors Among Patients With Type 2 Diabetes

Canadian Network for Observational Drug Effect Studies, CNODES 1249636 participants Est. completion 2019-12-01 1 site

Type 2 diabetes Other conditions: Urosepsis, Diabetic Ketoacidosis, Lower Extremity Amputation
View official trial listing →
Completed NCT NCT04081857

A Study to Evaluate the Pharmacokinetics and Safety of HCP1704 in Healthy Subjects

Not yet reported Hanmi Pharmaceutical Company Limited 48 participants Est. completion 2019-08-05 1 site

Other conditions: Health, Subjective
View official trial listing →
Completed NCT NCT04087525

A Study to Evaluate the Pharmacokinetics and Safety of HIP1701 in Healthy Subjects

Not yet reported Hanmi Pharmaceutical Company Limited 31 participants Est. completion 2018-11-27 1 site

Other conditions: Health, Subjective
View official trial listing →
Completed NCT NCT04237493

Dosage Reduction and Acute Glycemic Complications in People With Type 2 Diabetes Who Fast During Ramadan

Not yet reported University of Jordan 687 participants Est. completion 2017-07-24 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT04300790

Study to Evaluate the Effect of Metformin in the Prevention of HG in HR[+]/HER2[-] PIK3CA-mut Advanced BC Patients

Not yet reported MedSIR 69 participants Est. completion 2025-03-16 19 sites

Other conditions: Breast Cancer
View official trial listing →
Withdrawn NCT NCT04410341

The DPP-4 Inhibitor Vildagliptin as Adjunct in Major Depressive Disorder Patients

Not yet reported, Not yet reported Sadat City University Est. completion 2024-12-01 1 site

Other conditions: Major Depressive Disorder
View official trial listing →
Status unknown NCT NCT04485845

Metformin Versus Vildagliptin in Reducing Risk of Metabolic Syndrome Complications Progression

Not yet reported Cairo University 39 participants Est. completion 2020-09-30 1 site

Metabolic syndrome Other conditions: Diabete Type 2, Kidney Insufficiency
View official trial listing →
Completed NCT NCT04654676

DPP4 Inhibitor on Glycemic Variability

Not yet reported University Malaysia Sarawak 12 participants Est. completion 2019-08-31 1 site

Type 2 diabetes
View official trial listing →
Withdrawn NCT NCT04761861

Vildagliptin for Treatment of Antipsychotic-induced Dyslipidemia

Not yet reported Sadat City University Est. completion 2025-12-31 1 site

Other conditions: Schizophrenia, Dyslipidemias
View official trial listing →
Completed NCT NCT04841096

Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure

Not yet reported Laboratorios Silanes S.A. de C.V. 162 participants Est. completion 2024-05-15 5 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT04916093

Safety and Efficacy of Antidiabetic Drugs in Recently Diagnosed Patients With Type 2 Diabetes

Not yet reported Beni-Suef University 60 participants Est. completion 2020-12-15 1 site

Type 2 diabetes
View official trial listing →
Status unknown NCT NCT05041673

Anti-diabetic Drugs and Fatty Liver Management

Not yet reported Alexandria University 120 participants Est. completion 2022-09-30 1 site

Type 2 diabetes Other conditions: Fatty Liver, Nonalcoholic
View official trial listing →
Status unknown NCT NCT05102149

Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus

Not yet reported PegBio Co., Ltd. 672 participants Est. completion 2025-04 42 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT05329844

The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safeyt Profile of Test Product Compared to Reference Product Will be Assessed.

Not yet reported AET Laboratories Private Limited 66 participants Est. completion 2015-04

Other conditions: Diabetes Mellitus
View official trial listing →
Completed NCT NCT05329857

The Study Intends to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safety Profile of Test Product Compared to Reference Product Will be Evaluated.

Not yet reported AET Laboratories Private Limited 60 participants Est. completion 2016-03

Other conditions: To Determine Bioequivalence Under Fed Conditions
View official trial listing →
Completed NCT NCT05337969

The Study Aims to Show Bioequivalence of the Test Product and the Reference Reference Product in a Crossover Design Study Healthy Volunteers. Additionally, the Safety Profile of Test Product Compared to Reference Product Will be Assessed.

Not yet reported AET Laboratories Private Limited 60 participants Est. completion 2016-03

Other conditions: To Determine Bioequivalence Under Fed Conditions
View official trial listing →
Status unknown NCT NCT05347459

Cognitive Protective Effect of Newer Antidiabetic Drugs

Alexandria University 100 participants Est. completion 2023-12 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT05359432

Comparison of Empaglifozin and Vildagliptin in Type 2 Diabetes Mellitus

Not yet reported Getz Pharma 120 participants Est. completion 2021-08-18 1 site

Type 2 diabetes
View official trial listing →
Active, not recruiting NCT NCT05366868

Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus

Not yet reported National Center for Global Health and Medicine, Japan 567 participants Est. completion 2027-03-31 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT05369793

Clinical Study Evaluating the Safety and Efficacy of Roflumilast in Type 2 Diabetic Patients With Diabetic Neuropathy

Not yet reported Tanta University 60 participants Est. completion 2023-10-10 1 site

Type 2 diabetes Other conditions: Diabetic Neuropathies
View official trial listing →
Status unknown NCT NCT05429554

The Effect of Metformin and DPP4 Inhibitors on Cognition and Cardiovascular Protection in Type 2 Diabetic Patients

MTI University 60 participants Est. completion 2022-09 1 site

Type 2 diabetes
View official trial listing →
Status unknown NCT NCT05902468

Ursodeoxycholic Acid as add-on Therapy in Type 2 Diabetes Mellitus

Not yet reported, Not yet reported Tanta University 88 participants Est. completion 2024-11-28 2 sites

Type 2 diabetes
View official trial listing →
Status unknown NCT NCT06010992

Nitazoxanide as Adjuvant Therapy in Type 2 Diabetes Mellitus

Not yet reported Tanta University 70 participants Est. completion 2025-01-01 2 sites

Type 2 diabetes
View official trial listing →
Completed NCT NCT06068686

Vildagliptin Versus Glimepiride in Type 2 Diabetic Patients

Not yet reported Damanhour University 70 participants Est. completion 2024-12-01 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT06073600

Bioequivalence Study to Compare Metformin / Vildagliptin Versus Galvumet®

Not yet reported Reseach Laboratory of Clinical and Experimental Pharmacology 18 participants Est. completion 2022-11-13 1 site

Other conditions: Fed Conditions
View official trial listing →
Completed NCT NCT06103747

Bioequivalence Study to Compare Metformin / Vildagliptin (850 mg/50 mg) Versus Galvumet®

Not yet reported Reseach Laboratory of Clinical and Experimental Pharmacology 18 participants Est. completion 2023-08-15 1 site

Other conditions: Fed Conditions
View official trial listing →
Status unknown NCT NCT06244407

The Bioequivalence Study of Fixed-dose Combination of Vildagliptin and Metformin HCI 50/1000 mg FCT Under Fed Conditions

Not yet reported International Bio service 40 participants Est. completion 2024-06-02

Other conditions: Healthy Volunteer
View official trial listing →
Status unknown NCT NCT06248801

Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets

Not yet reported Bio-innova Co., Ltd 48 participants Est. completion 2024-10-15

Other conditions: Healthy Subjects
View official trial listing →
Completed NCT NCT06313008

Empagliflozin Versus Vildagliptin in CAD Patients With T2DM

Not yet reported Damanhour University 120 participants Est. completion 2024-10-10 1 site

Cardiovascular diseaseType 2 diabetes
View official trial listing →
Status unknown NCT NCT06449235

Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

Not yet reported Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders 938 participants Est. completion 2025-06 1 site

Other conditions: Type2diabetes
View official trial listing →
Status unknown NCT NCT06570980

Comparative Analysis of Cost-effectiveness Between Sulfonylureas and DPP4 Inhibitors in Combination With Metformin in Treatment of Type 2 Diabetic Patients : A Retrospective, Observational Study.

Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh 200 participants Est. completion 2024-08-30 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT06851962

Impact of Pharmacogenetic-Guided Treatment on Type 2 Diabetes.

Not yet reported Fundación para la Investigación del Hospital Clínico de Valencia 92 participants Est. completion 2026-06-30 3 sites

Type 2 diabetes
View official trial listing →
Active, not recruiting NCT NCT06889909

Comparison of Once-Weekly Trelagliptin Vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 Diabetes

Not yet reported Lahore General Hospital 102 participants Est. completion 2025-06-15 1 site

Type 2 diabetes
View official trial listing →
Active, not recruiting NCT NCT06913101

Comparison of Once-Weekly Trelagliptin vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 Diabetes

Not yet reported PNS Hafeez - Naval Hospital 102 participants Est. completion 2025-05-15 1 site

Type 2 diabetes
View official trial listing →
Not yet recruiting NCT NCT06951334

Clinical Trial of Vildagliptin in Early Parkinson's Disease

Not yet reported First Affiliated Hospital, Sun Yat-Sen University 66 participants Est. completion 2026-12-31

Other conditions: Parkinson's Disease
View official trial listing →
Completed NCT NCT07077525

Effect of Vildagliptin Versus Dapagliflozin as Add on Therapy to Metformin on Cardiovascular Risk Factors

Not yet reported Al-Azhar University 196 participants Est. completion 2024-08-31 1 site

Type 2 diabetes
View official trial listing →
Completed NCT NCT07677865

GLP-1 Receptor Agonists and Alzheimer's Disease: A Multi-National Target Trial Emulation

West China Hospital 213891 participants Est. completion 2026-06-24 1 site

Type 2 diabetes Other conditions: Alzheimer Disease, Obesity & Overweight
View official trial listing →
Not yet recruiting NCT NCT07811011

Efficacy of Dapagliflozin Versus Metformin in Patients With Polycystic Ovary Syndrome

Not yet reported, Not yet reported Tanta University 70 participants Est. completion 2027-03-30

Other conditions: Poly Cystic Ovary Syndrome
View official trial listing →

Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

ClinicalTrials.gov — NCT00230464

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.